Critical Contrast: MetLife (NYSE:MET) and SiriusPoint (NYSE:SPNT)

MetLife (NYSE:MET – Get Free Report) and SiriusPoint (NYSE:SPNT – Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.

Profitability

This table compares MetLife and SiriusPoint’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MetLife 6.21% 25.71% 0.92%
SiriusPoint 14.93% 15.89% 2.87%

Earnings and Valuation

This table compares MetLife and SiriusPoint”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MetLife $80.74 billion 0.79 $3.38 billion $7.67 13.19
SiriusPoint $3.35 billion 0.91 $459.60 million $4.11 6.42

MetLife has higher revenue and earnings than SiriusPoint. SiriusPoint is trading at a lower price-to-earnings ratio than MetLife, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MetLife has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, SiriusPoint has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Insider and Institutional Ownership

95.0% of MetLife shares are held by institutional investors. Comparatively, 52.8% of SiriusPoint shares are held by institutional investors. 0.4% of MetLife shares are held by company insiders. Comparatively, 12.2% of SiriusPoint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for MetLife and SiriusPoint, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MetLife 0 1 14 0 2.93
SiriusPoint 0 3 3 1 2.71

MetLife currently has a consensus price target of $107.12, indicating a potential upside of 5.88%. SiriusPoint has a consensus price target of $30.67, indicating a potential upside of 16.25%. Given SiriusPoint’s higher possible upside, analysts plainly believe SiriusPoint is more favorable than MetLife.

Summary

MetLife beats SiriusPoint on 9 of the 15 factors compared between the two stocks.

About MetLife

(Get Free Report)

MetLife, Inc. is a global financial services company best known for providing insurance, employee benefits and retirement-related products. Its offerings include life, dental and disability insurance, annuities, and products and services designed to help individuals and employers plan for financial protection and retirement. The company serves individuals, businesses and institutions in the United States and international markets, including countries in Latin America, Asia, Europe and the Middle East.

About SiriusPoint

(Get Free Report)

SiriusPoint Ltd. is a Bermuda-based global insurer and reinsurer that provides specialty insurance and reinsurance products to businesses and other organizations. Its offerings span areas such as property and casualty, accident and health, and other specialty risks. The company works with brokers, agents, managing general agents and other distribution partners to underwrite risks across a range of markets. Its business serves clients in the United States and internationally, including in Europe and other regions.

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.